Is the third generation EGFR TKIs the solution for making EGFR mutant NSCLC a curable disease?

Lignende værker

• Postoperative adjuvant EGFR-TKIs for resected EGFR-mutant NSCLC—opportunities and obstacles
  af: Parris, Brielle A., et al.
  Udgivet: (2021)
• Does TMB impact the effectiveness of TKIs in EGFR-mutant NSCLC?
  af: Cheng, Michael L., et al.
  Udgivet: (2018)
• Risk factors for radiation pneumonitis in NSCLC patients treated with third-generation EGFR TKIs and chest radiotherapy
  af: Nan Zhao, et al.
  Udgivet: (2025-05-01)
• Third generation EGFR TKIs: current data and future directions
  af: Tan, Chee-Seng, et al.
  Udgivet: (2018)
• Making progress in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer by surpassing resistance: third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs)
  af: Mountzios, Giannis
  Udgivet: (2018)